ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Presidio Management Group XII, L.L.C. (10% Owner)
Reporting Person: U.S. Venture Partners XII, L.P. (10% Owner)
Reporting Person: U.S. Venture Partners XII-A, L.P. (10% Owner)
Reporting Person: Tansey Casey M (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (1779969)		Indirect
Series B Preferred Stock	$		Common Stock (90335)		Indirect
Series C Preferred Stock	$		Common Stock (289198)		Indirect
Series C Preferred Stock	$		Common Stock (14677)		Indirect

Footnotes

F1: All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII Funds. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have sole dispositive power over the reported securities held by the USVP XII Funds and is a managing member of PMG XII and may be deemed to have shared voting power over the reported securities held by the USVP XII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.